Cerevel Therapeutics announced Thursday that its once-a-day oral drug candidate for Parkinson's disease, tavapadon, has achieved key goals in a key phase 3 trial as a combination therapy.
The Zhitong Finance App learned,$AbbVie (ABBV.US)$The subject of the acquisition$Cerevel Therapeutics Holdings (CERE.US)$It was announced on Thursday that its once-a-day oral drug candidate for Parkinson's disease, tavapadon, has achieved key goals in a critical phase III trial as a combination therapy.
The company said that the TEMPO-3 study on adult patients with advanced Parkinson's disease showed clinical significance and significant statistical differences in terms of primary endpoints between tavapadone and brain therapy levodopa compared with placebo plus levodopa.
This 27-week study of 507 patients used the change in the total “start up” time without movement disorder compared to the baseline hypothesis. The results showed that compared with the placebo control group (1.7 hours vs. 0.6 hours), the “start up” time of the medication group increased by 1.1 hours.
Furthermore, compared with the placebo control group, there was also a statistically significant reduction in the key secondary endpoint “shutdown” time in the tampadonga-levodopa group.
Regarding safety, the company added that the studied drugs were well tolerated and most adverse reactions were mild to moderate.
Cerevel hopes to use these findings to support future regulatory applications for tavapadone. Topline data for the candidate's two late-stage monotherapy trials in Parkinson's disease is expected to be released in the second half of 2024.
In December of last year, AbbVie agreed to buy Cerevel for $8.7 billion. Since Cerevel is a leading developer of drugs for schizophrenia, its rival$Reviva Pharmaceuticals (RVPH.US)$und$Bristol-Myers Squibb (BMY.US)$Acquired in March$Karuna Therapeutics (KRTX.US)$It also rose along with it. According to reports, AbbVie's all-cash acquisition of Cerevel is expected to be completed in mid-2024.